Although retrospective clinical studies have demonstrated that combination therapy can extend the survival of MM patients (98) dedicated Phase III clinical trials are still lacking.Idelalisib targets Phosphoinositide 3 - Kinase (PI3K), inhibiting the PI3K/Akt/mTOR pathway to disrupt the survival and proliferation signals of MM cells (99). The gene discussed is AKT1; the disease is Miyoshi myopathy.